• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

    21.68 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Sarepta Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    35 36 Next >
    News headline image
    Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
    CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ: SRPT) skyrocketed 35% in early trading today, reaching levels not seen since the company’s early days in Duchenne Muscular... 
    Via MarketMinute
    News headline image
    Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
    CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years.... 
    Via MarketMinute
    News headline image
    The RNA Renaissance: Decoding Sarepta Therapeutics’ 34% Surge and the Future of Precision Medicine
    On March 25, 2026, the biotechnology sector witnessed a tectonic shift as Sarepta Therapeutics (NASDAQ: SRPT) saw its share price skyrocket by 34% in a single trading session. This dramatic surge—the... 
    Via Finterra
    Topics Retirement
    Sarepta Therapeutics (NASDAQ:SRPT) Posts Q4 Revenue Beat Amid Deep Losses and Major Charges ↗
    Via Chartmill
    Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
    Via Chartmill
    Wednesday's session: top gainers and losers ↗
    Via Chartmill
    Which stocks are gapping on Wednesday? ↗
    Via Chartmill
    News headline image
    Sarepta Therapeutics (SRPT) at a Crossroads: A 2026 Deep Dive into the Future of Genetic Medicine
    As of March 25, 2026, Sarepta Therapeutics (NASDAQ: SRPT) stands at a pivotal, albeit bruising, crossroads in the history of genetic medicine. Once the darling of the biotechnology sector for its... 
    Via Finterra
    Topics Economy Intellectual Property Retirement
    Why Did SRPT Stock Rise 6% In Pre-Market Today? ↗
    Via Stocktwits
    News headline image
    Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    2 Beaten-Down Stocks That Still Aren't Worth Buying ↗
    These stocks aren't nearly as cheap as they look. 
    Via The Motley Fool
    Topics Cannabis
    News headline image
    Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study ↗
    Data from the study cohort is aimed at determining whether administering sirolimus prior to and after Elevidys infusion can help reduce risks associated with the gene therapy. 
    Via Stocktwits
    Topics Death
    News headline image
    Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Nasdaq, S&P 500 Futures Tread Caution On Nvidia’s China Risk: Why NFLX, WBD, AAPL, CRM, AI, LRMR Are On Traders' Radar Today ↗
    Data from Stocktwits showed that retail sentiment on SPY and QQQ diverged. 
    Via Stocktwits
    Topics Artificial Intelligence ETFs Stocks
    News headline image
    Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat ↗
    A new Cohort 8 study aims to reopen the non-walking patient market with data expected by the end of 2026. 
    Via Stocktwits
    Topics Earnings
    News headline image
    Sarepta (SRPT) Q4 2025 Earnings Call Transcript ↗
    Sarepta (SRPT) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling ↗
    Institutional support remains strong in February, with 134 investors increasing positions and 61 initiating new stakes. 
    Via Stocktwits
    Topics Intellectual Property
    News headline image
    Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy ↗
    While Sarepta’s gene therapy for the treatment of DMD called Elevidys was approved by the FDA in 2023, Regenxbio is developing its treatment. 
    Via Stocktwits
    Topics Intellectual Property Lawsuit
    News headline image
    Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    News headline image
    Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    Which stocks are moving after the closing bell on Friday? ↗
    Via Chartmill
    News headline image
    Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy
    From Sarepta Therapeutics, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    35 36 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.